Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Michael D. Jain, Miriam T. Jacobs, Loretta J. Nastoupil, Jay Y. Spiegel, Gao Feng, Yi Lin, Matthew A. Lunning, Saurabh Dahiya, Lazaros J Lekakis, Patrick M Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Andre Goy, Brian T. Hill, Javier Munoz, Julio Chavez, Aaron P. Rapoport, Julie M Vose, David B Miklos, Sattva S Neelapu, N. Nora Bennani, Charalambos Andreadis, Alison R. Sehgal, Armin Ghobadi, Frederick L. Locke
Institutions: Moffitt Cancer Center, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Stanford Medicine, Stanford University, Mayo Clinic, University of Nebraska Medical Center, University of Miami, University of Rochester Medicine, University of Rochester, Vanderbilt University Medical Center, University of Kansas Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Hackensack University Medical Center, Cleveland Clinic, Banner MD Anderson Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, UPMC Hillman Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2991231480